UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.079

Sortiert nach

Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer

Journal of thoracic oncology, 2016-07, Vol.11 (7), p.976-988

2016

Volltextzugriff (PDF)

Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting

PloS one, 2017-06, Vol.12 (6), p.e0178420

2017

Volltextzugriff (PDF)

Patients' voice and passion lead to successful clinical trial, KISEKI study; Comments on “A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy”

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.143-144

2023

Volltextzugriff (PDF)

Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy

Journal of thoracic oncology, 2015-07, Vol.10 (7), p.974-984

2015

Volltextzugriff (PDF)

Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors

Journal of thoracic oncology, 2021-07, Vol.16 (7), p.1086-1098

2021

Volltextzugriff (PDF)

PDL1 Regulation by p53 via miR-34

JNCI : Journal of the National Cancer Institute, 2016-01, Vol.108 (1), p.1

2016

Volltextzugriff (PDF)

DLL3: an emerging target in small cell lung cancer

Journal of hematology and oncology, 2019-06, Vol.12 (1), p.61-61, Article 61

2019

Volltextzugriff (PDF)

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

Clinical cancer research, 2019-12, Vol.25 (23), p.6958-6966

2019

Volltextzugriff (PDF)

Depression in association with neutrophil-to-lymphocyte, platelet-to-lymphocyte, and advanced lung cancer inflammation index biomarkers predicting lung cancer survival

PloS one, 2023-02, Vol.18 (2), p.e0282206-e0282206

2023

Volltextzugriff (PDF)

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

Journal of clinical oncology, 2012-03, Vol.30 (8), p.863-870

2012

Volltextzugriff (PDF)

Non-small-cell lung cancer

Nature reviews. Disease primers, 2015-05, Vol.1 (1), p.15009-15009, Article 15009

2015

Volltextzugriff (PDF)

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Nature medicine, 2022-10, Vol.28 (10), p.2155-2161

2022

Volltextzugriff (PDF)

SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer

Clinical cancer research, 2016-05, Vol.22 (10), p.2396-2404

2016

Volltextzugriff (PDF)

Circulating MicroRNAs and Extracellular Vesicle–Containing MicroRNAs as Response Biomarkers of Anti–programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC

Journal of thoracic oncology, 2020-11, Vol.15 (11), p.1773-1781

2020

Volltextzugriff (PDF)

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

Journal of thoracic oncology, 2018-09, Vol.13 (9), p.1248-1268

2018

Volltextzugriff (PDF)

Development of new techniques and clinical applications of liquid biopsy in lung cancer management

Science bulletin, 2024-05, Vol.69 (10), p.1556-1568

2024

Volltextzugriff (PDF)

Response to the Letter to the Editor Titled “First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA”

Journal of thoracic oncology, 2023-09, Vol.18 (9), p.e102-e103

2023

Volltextzugriff (PDF)

Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater

Lung cancer (Amsterdam, Netherlands), 2019-12, Vol.138, p.88-94

2019

Volltextzugriff (PDF)

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

Journal of thoracic oncology, 2016-07, Vol.11 (7), p.946-963

2016

Volltextzugriff (PDF)

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial

The lancet oncology, 2016-12, Vol.17 (12), p.1661-1671

2016

Volltextzugriff (PDF)

EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19), p.5572-5584

2014

Volltextzugriff (PDF)

Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer

BMC cancer, 2024-04, Vol.24 (1), p.424-424, Article 424

2024

Volltextzugriff (PDF)

Real-world treatment patterns and outcomes of patients with metastatic nonsquamous non-small cell lung cancer after progression on standard-of-care therapy in the United States

Lung cancer (Amsterdam, Netherlands), 2023-05, Vol.179, p.107177-107177, Article 107177

2023

Volltextzugriff (PDF)

1 – 25 von 1.079

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(997)
Mit Volltextzugriff
(994)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Research
(85)
Journal Of Clinical Oncology
(84)
Journal Of Thoracic Oncology
(70)
Clinical Cancer Research
(27)
Lung Cancer
(21)
Clinical Lung Cancer
(15)
Journal Of Hepatology
(15)
Journal For Immunotherapy Of Cancer
(14)
Atmospheric Chemistry And Physics
(11)
Nature
(11)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer

Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy

Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors

PDL1 Regulation by p53 via miR-34

DLL3: an emerging target in small cell lung cancer

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

Depression in association with neutrophil-to-lymphocyte, platelet-to-lymphocyte, and advanced lung cancer inflammation index biomarkers predicting lung cancer survival

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

Non-small-cell lung cancer

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer

Circulating MicroRNAs and Extracellular Vesicle–Containing MicroRNAs as Response Biomarkers of Anti–programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

Development of new techniques and clinical applications of liquid biopsy in lung cancer management

Response to the Letter to the Editor Titled “First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA”

Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial

EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling

Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer

Real-world treatment patterns and outcomes of patients with metastatic nonsquamous non-small cell lung cancer after progression on standard-of-care therapy in the United States

Suchergebnisse filtern